Biogen (BIIB) Stock Forecast & Price Target

Compare

4,890 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

11 Buy

14 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$170.70

▲(22.70% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $170.70 with a high forecast of $260.00 and a low forecast of $118.00. The average price target represents a 22.70% change from the last price of $139.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","153":"$153","189":"$189","225":"$225","261":"$261"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$170.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$118.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,153,189,225,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.95,141.79999999999998,151.64999999999998,161.5,171.35,181.2,191.05,200.9,210.75,220.6,230.45,240.3,250.15,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.95,134.93076923076922,137.91153846153844,140.89230769230767,143.87307692307692,146.85384615384615,149.83461538461538,152.8153846153846,155.79615384615383,158.77692307692305,161.7576923076923,164.73846153846154,167.71923076923076,{"y":170.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.95,130.87692307692308,129.80384615384614,128.73076923076923,127.6576923076923,126.58461538461538,125.51153846153845,124.43846153846154,123.36538461538461,122.29230769230769,121.21923076923076,120.14615384615385,119.07307692307693,{"y":118,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":210.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$260.00

Average Price Target$170.70

Lowest Price Target$118.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Biogen (BIIB) Gets a Hold from Bernstein

David Amsellem

Piper Sandler

$115→$118

Hold

-15.18%

Downside

Reiterated

08/14/25

Biogen price target raised to $118 from $115 at Piper SandlerBiogen price target raised to $118 from $115 at Piper Sandler

Salveen Richter

Goldman Sachs

$197

Buy

41.60%

Upside

Reiterated

08/05/25

Biogen's Strong Performance and Growth Prospects in Alzheimer's Treatment Justify Buy Rating

Sumant Kulkarni

Canaccord Genuity

$220

Buy

58.14%

Upside

Reiterated

08/04/25

Biogen's Strong Financial Performance and Strategic Pipeline Drive Buy Rating

Evan Seigerman

BMO Capital

$128

Hold

-7.99%

Downside

Reiterated

08/04/25

BMO Capital Sticks to Their Hold Rating for Biogen (BIIB)

Thomas Shrader

BTIG

―

Hold

―

Reiterated

08/04/25

Biogen's Mixed Prospects: Hold Rating Amid Growth and Technological Challenges

Salim Syed

Mizuho Securities

$169

Buy

21.48%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Incyte (NASDAQ: INCY)BIIB (OP, maintaining PT at $169): No major changes to our model.

Andrew Fein

H.C. Wainwright

$187→$194

Buy

39.45%

Upside

Reiterated

08/01/25

Promising Developments in Biogen's IgAN Treatments Drive Buy Rating

Marc Goodman

Leerink Partners

$260

Buy

86.89%

Upside

Reiterated

08/01/25

Biogen's Strategic Pipeline Diversification and Promising Product Performance Drive Buy Rating

Yatin Suneja

Guggenheim

$165

Buy

18.60%

Upside

Reiterated

08/01/25

Guggenheim Sticks to Their Buy Rating for Biogen (BIIB)

Ami Fadia

Needham

―

Hold

―

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Biogen (NASDAQ: BIIB) and Conmed (NYSE: CNMD)

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

08/01/25

Biogen (BIIB) Receives a Hold from Truist Financial

Geoff Meacham

Citi

$125→$135

Hold

-2.96%

Downside

Reiterated

08/01/25

Biogen price target raised to $135 from $125 at CitiBiogen price target raised to $135 from $125 at Citi

George Farmer

Scotiabank

$224

Buy

61.01%

Upside

Reiterated

08/01/25

Biogen (BIIB) Receives a Buy from Scotiabank

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/25

Biogen's Strong Performance and Positive Outlook Drive Buy RatingWe note this includes a one-time shipment to China of approximately $35 million. Skyclarys achieved second-quarter sales of $130 million, but the commercial focus remains on Leqembi, which has seen only modest growth relative to expectations, in our view. The legacy MS franchise also outperformed expectations this quarter, but we continue to expect genericization pressures and increased anti-CD20 utilization will erode this franchise as a growth driver for Biogen. Adjusted net income of $803 million ($5.47/share) was above our estimate of $603 million ($4.11/share) and consensus of $583 million ($4.10/share). We provide consolidated variance from our estimates in exhibit 1 on page 2 of the note.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Biogen (BIIB) Gets a Hold from Bernstein

David Amsellem

Piper Sandler

$115→$118

Hold

-15.18%

Downside

Reiterated

08/14/25

Biogen price target raised to $118 from $115 at Piper SandlerBiogen price target raised to $118 from $115 at Piper Sandler

Salveen Richter

Goldman Sachs

$197

Buy

41.60%

Upside

Reiterated

08/05/25

Biogen's Strong Performance and Growth Prospects in Alzheimer's Treatment Justify Buy Rating

Sumant Kulkarni

Canaccord Genuity

$220

Buy

58.14%

Upside

Reiterated

08/04/25

Biogen's Strong Financial Performance and Strategic Pipeline Drive Buy Rating

Evan Seigerman

BMO Capital

$128

Hold

-7.99%

Downside

Reiterated

08/04/25

BMO Capital Sticks to Their Hold Rating for Biogen (BIIB)

Thomas Shrader

BTIG

―

Hold

―

Reiterated

08/04/25

Biogen's Mixed Prospects: Hold Rating Amid Growth and Technological Challenges

Salim Syed

Mizuho Securities

$169

Buy

21.48%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Incyte (NASDAQ: INCY)BIIB (OP, maintaining PT at $169): No major changes to our model.

Andrew Fein

H.C. Wainwright

$187→$194

Buy

39.45%

Upside

Reiterated

08/01/25

Promising Developments in Biogen's IgAN Treatments Drive Buy Rating

Marc Goodman

Leerink Partners

$260

Buy

86.89%

Upside

Reiterated

08/01/25

Biogen's Strategic Pipeline Diversification and Promising Product Performance Drive Buy Rating

Yatin Suneja

Guggenheim

$165

Buy

18.60%

Upside

Reiterated

08/01/25

Guggenheim Sticks to Their Buy Rating for Biogen (BIIB)

Ami Fadia

Needham

―

Hold

―

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Biogen (NASDAQ: BIIB) and Conmed (NYSE: CNMD)

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

08/01/25

Biogen (BIIB) Receives a Hold from Truist Financial

Geoff Meacham

Citi

$125→$135

Hold

-2.96%

Downside

Reiterated

08/01/25

Biogen price target raised to $135 from $125 at CitiBiogen price target raised to $135 from $125 at Citi

George Farmer

Scotiabank

$224

Buy

61.01%

Upside

Reiterated

08/01/25

Biogen (BIIB) Receives a Buy from Scotiabank

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

1 Month

xxx

Success Rate

15/32 ratings generated profit

Average Return

+0.65%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.88% of your transactions generating a profit, with an average return of +0.65% per trade.

3 Months

xxx

Success Rate

16/32 ratings generated profit

Average Return

-0.62%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.62% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

13/34 ratings generated profit

Average Return

-7.79%

reiterated a buy rating 23 days ago

Copying Marc Goodman's trades and holding each position for 1 Year would result in 38.24% of your transactions generating a profit, with an average return of -7.79% per trade.

2 Years

xxx

Success Rate

13/40 ratings generated profit

Average Return

-18.97%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 32.50% of your transactions generating a profit, with an average return of -18.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 36 Buy Ratings, 36 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is 170.70.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.84 with a range of $2.85 to $4.60. The previous quarter’s EPS was $5.47. BIIB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.34B with a range of $2.26B to $2.45B. The previous quarter’s sales results were $2.56B. BIIB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.24% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 170.70.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 22.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 14 hold ratings and 0 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is 170.70. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $260.00 ,the lowest forecast is $118.00. The average price target represents 22.70% Increase from the current price of $139.12.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts